Annex B: ASEAN Dx Initiative
Project Evaluation Criteria

 

i. Strategic Fit to ASEAN Member States

  • Health impact to ASEAN member state
    (e.g. Does the product reduce cost to healthcare delivery?)

ii. Value Proposition
a. Medical Value

  • Addresses unmet medical needs
  • Clear and viable intended use
  • Clinical utility (effectiveness, practicability, accessibility, acceptability)
  • Provides early window for therapeutic intervention
  • Aligns with local clinical KOLs, clinical strengths & interests

b. Workflow Efficiency

  • Labour saving and cost reduction
  • Minimal packaging and waste
  • Minimal to no training required
  • Enhances productivity in healthcare sector
  • Fits into existing clinical diagnostics and patient management workflows

c. Performance Characteristics

  • Accuracy, safety and reliability
  • Analytical performance: eg. detection limit, accuracy & precision, QC
  • Clinical performance: eg. false positives & negatives, correlations, actionable results

iii. Competition, Partnerships, Regulatory Pathway
a. Competitive Landscape

  • Comparison of proposed solution against the existing solutions (What is the unique selling point?)
  • Competing emerging technologies and start-ups (ie. can it easily be copied?)
  • Freedom to operate / execute (IP)
  • Cost & speed of in-licensing

b. Development Roadmap

  • Regulatory hurdle, commercial deployment pathway
  • Workplan, deliverables & budget

c. Development Bandwidth

  • Can the industry partner execute development & commercialization
  • Access to clinical specimens and patients
  • Involvement of local development partner

iv. Market and Operationalization
a. Commercial Attractiveness

  • Size of addressable market
  • Niche market segmentation
  • New market creation

b. Product Commercial Viability

  • Clear go-to-market roadmap (eg. user, payor, government buy-in, health economics etc.)
  • Product manufacturability and/or outsourcing plans
  • Product cost and scalability
  • Market adoption and access
  • Viable and sustainable supply chain

c. Commercialization Party Profile

  • Co-development commitment
  • Potential licensee credibility or track record
  • Further funding downstream
  • Commitment to co-funding (through host country or enterprise)